Abeona Therapeutics (NASDAQ:ABEO) Stock Lifted to “Hold” by Wall Street Zen

Wall Street Zen upgraded shares of Abeona Therapeutics (NASDAQ:ABEO – Free Report) from a sell rating to a hold rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.

Several other equities research analysts have also recently issued reports on ABEO. Oppenheimer reaffirmed an “outperform” rating and set a $21.00 price objective (down from $22.00) on shares of Abeona Therapeutics in a research report on Friday, August 14th. HC Wainwright reiterated a “buy” rating on shares of Abeona Therapeutics in a research note on Friday, September 25th. Roth Capital assumed coverage on Abeona Therapeutics in a report on Thursday, September 17th. They issued a “buy” rating and a $17.00 target price on the stock. Cantor Fitzgerald raised their price target on Abeona Therapeutics from $28.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, September 18th. Finally, UBS Group restated a “buy” rating on shares of Abeona Therapeutics in a research note on Friday, September 25th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $21.00.

Check Out Our Latest Report on Abeona Therapeutics

Abeona Therapeutics Trading Up 5.7%

NASDAQ:ABEO traded up $0.13 during mid-day trading on Friday, hitting $2.42. The stock had a trading volume of 3,175,970 shares, compared to its average volume of 2,019,228. The stock has a 50-day simple moving average of $4.70 and a two-hundred day simple moving average of $5.39. The company has a market capitalization of $138.30 million, a PE ratio of -2.26 and a beta of 1.50. Abeona Therapeutics has a twelve month low of $2.09 and a twelve month high of $7.65.

Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) last issued its quarterly earnings results on Monday, November 9th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.09. Abeona Therapeutics had a negative net margin of 160.30% and a negative return on equity of 44.82%. The company had revenue of $13.49 million during the quarter, compared to the consensus estimate of $14.82 million. Sell-side analysts predict that Abeona Therapeutics will post -1.00 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Vishwas Seshadri sold 19,608 shares of the business’s stock in a transaction that occurred on Tuesday, September 29th. The shares were sold at an average price of $5.16, for a total transaction of $101,177.28. Following the completion of the sale, the chief executive officer owned 1,286,500 shares in the company, valued at approximately $6,638,340. The trade was a 1.50% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Brendan M. O’malley sold 6,727 shares of the business’s stock in a transaction that occurred on Tuesday, September 29th. The stock was sold at an average price of $5.16, for a total transaction of $34,711.32. Following the sale, the senior vice president owned 421,226 shares of the company’s stock, valued at $2,173,526.16. This represents a 1.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 55,428 shares of company stock valued at $296,508 over the last three months. 7.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Abeona Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ABEO. Global Retirement Partners LLC lifted its position in Abeona Therapeutics by 1,026.2% in the third quarter. Global Retirement Partners LLC now owns 4,978 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 4,536 shares during the last quarter. Royal Bank of Canada grew its holdings in shares of Abeona Therapeutics by 49.6% during the first quarter. Royal Bank of Canada now owns 6,500 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 2,155 shares during the last quarter. Dimensional Fund Advisors LP purchased a new position in shares of Abeona Therapeutics during the first quarter worth about $154,000. WINTON GROUP Ltd acquired a new stake in shares of Abeona Therapeutics during the second quarter worth about $256,000. Finally, Rangeley Capital LLC increased its position in shares of Abeona Therapeutics by 4.2% during the first quarter. Rangeley Capital LLC now owns 60,000 shares of the biopharmaceutical company’s stock worth $269,000 after purchasing an additional 2,400 shares in the last quarter. 80.56% of the stock is currently owned by institutional investors and hedge funds.

Abeona Therapeutics News Roundup

Here’s some of the latest news about ABEO:

  • Positive Sentiment: HC Wainwright raised its FY2026 loss estimate to $0.96 per share from $1.15 and trimmed its Q4 2026 projected loss to $0.22 from $0.24. Abeona Therapeutics analyst estimates
  • Positive Sentiment: Wall Street Zen raised its rating on ABEO to Hold, a modestly improved assessment. Abeona Therapeutics rating update
  • Negative Sentiment: HC Wainwright cut its FY2027 estimate to a $0.82-per-share loss from $0.49 and lowered its forecasts for each 2027 quarter, signaling expectations for greater losses. Separate coverage cited growing concern about the pace of Zevaskyn’s sales ramp, a potential headwind to investor expectations. Zevaskyn ramp concerns

Abeona Therapeutics Company Profile

(Get Free Report)

Abeona Therapeutics, Inc. is a biotechnology company focused on developing cell and gene therapies for serious and rare diseases. Its work includes treatments designed to address the underlying genetic causes of disease. The company’s lead product, ZEVASKYN (prademagene zamikeracel), is an autologous gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, a rare inherited skin disorder. Made from a patient’s skin cells, the therapy uses genetic modification to help cells produce type VII collagen and is applied to wounds.

Recommended Stories

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.